U.S. Markets closed

Here's Why You Should Retain Cardinal Health Stock for Now

Zacks Equity Research

Cardinal Health Inc. CAH is well poised for growth backed by diversified product portfolio, acquisition-driven strategy and robust pharmaceutical segment. However, integration risks remain a concern.

The stock currently carries a Zacks Rank #3 (Hold).

Price Performance

Shares of Cardinal Health have gained 5.8%, compared with the industry’s growth of 9.7% on a year-to-date basis. Further, the S&P 500 Index rallied 16.8% in the same timeframe.



What’s Weighing on the Stock?

The company’s acquisition-driven strategy makes it susceptible to integration risks.

Moreover, intense competition in each of the business segments remains a concern.

Factors to Bolster Cardinal Health

Cardinal Health’s Medical and Pharmaceutical offerings provide the company a competitive edge in the niche space. It offers industry expertise and an expanding portfolio of safe products.

The company follows an acquisition-driven strategy and remains committed toward investment in key growth businesses to gain market traction and bolster profits.

The company’s Pharmaceutical segment boasts of being the second largest pharmaceutical distributor in the United States. The segment’s products and services consist of pharmaceutical distribution, manufacturer and specialty services, and nuclear and pharmacy services. These in turn are anticipated to drive the company in the days ahead.

In terms of costs, Cardinal Health announced in fourth-quarter fiscal 2019 earnings call that it anticipates incremental cost savings of $130 million associated with actions intended to optimize and simplify its operating model and cost structure.

In fact, the company has already delivered $130 million in fiscal 2019. The company remains confident when it comes to generating more than $500 million in savings in comparison with its fiscal 2018 baseline in five years or less. This is likely to aid the company’s margins in the days ahead.

Which Way Are Estimates Headed?

For fiscal 2020, the Zacks Consensus Estimate for revenues is pegged at $152.71 billion, indicating an improvement of 4.9% from the year-ago period. For adjusted earnings per share, the same stands at $5.01, suggesting a decline of 5.1% from the year-ago reported figure.

Key Picks

Some better-ranked stocks from the broader medical space are AmerisourceBergen Corporation ABC, DENTSPLY SIRONA Inc. XRAY and McKesson Corporation MCK, each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

AmerisourceBergen has a long-term earnings growth rate of 7.9%.

DENTSPLY SIRONA has a long-term earnings growth rate of 11.6%.

McKesson has a long-term earnings growth rate of 6.9%.

Free: Zacks’ Single Best Stock Set to Double

Today you are invited to download our just-released Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.